Development of implantation substrates for the collection of radionuclides of medical interest produced via ISOL technique at INFN-LNL

Ballan, M.; Vettorato, Elisa; Morselli, L.; Tosato, Marianna; Nardella, Sonia; Borgna, Francesca; Corradetti, S.; Monetti, A.; Lunardon, M.; Zenoni, A.; Marco, Valerio Di; Realdon, Nicola; Andrighetto, A.

doi:10.1016/j.apradiso.2021.109795

Cited by 8 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, it was demonstrated that the deposition of silver, as well as different metals, occurs within less than 0.5 mm from the target surface. Thus, this study confirmed the possibility of using low-porosity materials for metal depositions without completely dissolving the implantation substrate to recover the deposited atoms [18]. An automated system for the deposition targets handling is currently under development and validation at LNL to insert and extract the substrates without the operators' radiation exposure.…”

Section: Isol Production: Silver Ionization Detection and Depositionsupporting

confidence: 68%

A New Production Method of High Specific Activity Radionuclides Towards Innovative Radiopharmaceuticals: The Isolpharm Project

Vettorato¹,

Morselli²,

Ballan³

et al. 2022

RAD Conference Proceedings

View full text Add to dashboard Cite

Radionuclides of interest in nuclear medicine are generally produced in cyclotrons or nuclear reactors, with associated issues such as highly enriched target costs and undesired contaminants. The ISOLPHARM project (ISOL technique for radioPHARMaceuticals) explores the feasibility of producing extremely high specific activity βemitting radionuclides as radiopharmaceutical precursors. This technique is expected to produce radiopharmaceuticals very hardly obtained in standard production facilities. Radioactive isotopes will be obtained from nuclear reactions induced by accelerating 40 MeV protons in a cyclotron to collide on a UCx target. By means of: high working temperatures and high vacuum conditions, the migration of the radioactive elements towards an ion source, a potential difference up to 40 kV, and a mass separation device, an isobaric beam of desired radionuclides will be produced and implanted on a deposition target. The availability of innovative isotopes can potentially open a new generation of radiopharmaceuticals, based on nuclides never studied so far. Among these, a very promising isotope could be Ag-111, a βemitter with a half-life (7.45 d), an average βenergy of 360 keV, a tissue penetration of around 1 mm, and a low percentage of γ-emission. The proof of principle studies on Ag-111 production and radiolabeling are currently under investigation in the ISOLPHARM_EIRA project, where both its production and possible application as a radiopharmaceutical precursor will be evaluated in its computational/physics, radiochemistry, and radiobiology tasks. Currently, innovative macromolecules meeting the specific requirements for the chelation and targeted delivery of Ag-111 are being developed, which will be further tested in vitro on 2D and 3D models, as well as in vivo for their pharmacokinetics and therapeutic potential onto xenograft models.

show abstract

Section: Isol Production: Silver Ionization Detection and Depositionsupporting

confidence: 68%

A New Production Method of High Specific Activity Radionuclides Towards Innovative Radiopharmaceuticals: The Isolpharm Project

Vettorato¹,

Morselli²,

Ballan³

et al. 2022

RAD Conference Proceedings

View full text Add to dashboard Cite

show abstract

“…Subsequently, the so-generated ion beam is extracted and directed to a magnet where all the concurrently produced non-isobaric species are separated. After the mass-separation step, the isobaric radioactive beam containing the radionuclide of interest is dumped on an implantation substrate for the collection [ 38 , 39 ].…”

Section: Separation Of Silver Radioisotopesmentioning

confidence: 99%

Section: Separation Of Silver Radioisotopesmentioning

confidence: 99%

“…In this context, the Legnaro National Laboratories of the Italian Institute of Nuclear Physics prompted a line of research aimed at the production of 111 Ag via the ISOL technique in the framework of the ISOLPHARM (“ISOL technique for radioPHARMaceuticals”) project [ 38 , 40 , 41 ]. Given that the facility is currently under construction, only theoretical calculations and off-line experiments have been conducted so far [ 38 , 41 ]. According to these calculations, 111 Ag could be produced with elevated production rates and extremely high purity (e.g., in-target production equal to 9.5 GBq after 0.5 d of irradiation and 83 GBq after 5 d of irradiation) by bombarding a uranium carbide target with a 40 MeV proton beam (200 μA) [ 38 , 41 ].…”

Section: Separation Of Silver Radioisotopesmentioning

confidence: 99%

“…Given that the facility is currently under construction, only theoretical calculations and off-line experiments have been conducted so far [ 38 , 41 ]. According to these calculations, 111 Ag could be produced with elevated production rates and extremely high purity (e.g., in-target production equal to 9.5 GBq after 0.5 d of irradiation and 83 GBq after 5 d of irradiation) by bombarding a uranium carbide target with a 40 MeV proton beam (200 μA) [ 38 , 41 ]. Indeed, after the mass separation stage, only the isobaric contaminant 111 Cd is expected to be collected along with 111 Ag [ 37 , 38 , 41 ], but it can be removed by dedicated chemical processing steps as described in the previous paragraphs [ 37 ].…”

Section: Separation Of Silver Radioisotopesmentioning

confidence: 99%

See 2 more Smart Citations

Lights and Shadows on the Sourcing of Silver Radioisotopes for Targeted Imaging and Therapy of Cancer: Production Routes and Separation Methods

Tosato

Asti

2023

Pharmaceuticals

View full text Add to dashboard Cite

The interest in silver radioisotopes of medical appeal (silver-103, silver-104m,g and silver-111) has been recently awakened by the versatile nature of their nuclear decays, which combine emissions potentially suitable for non-invasive imaging with emissions suited for cancer treatment. However, to trigger their in vivo application, the production of silver radioisotopes in adequate amounts, and with high radionuclidic purity and molar activity, is a key prerequisite. This review examines the different production routes of silver-111, silver-103 and silver-104m,g providing a comprehensive critical overview of the separation and purification strategies developed so far. Aspects of quality (radiochemical, chemical and radionuclidic purity) are also emphasized and compared with the aim of pushing towards the future implementation of this theranostic triplet in preclinical and clinical contexts.

show abstract

Production and characterization of 111Ag radioisotope for medical use in a TRIGA Mark II nuclear research reactor

Morselli

Donzella

Arzenton

et al. 2023

Applied Radiation and Isotopes

View full text Add to dashboard Cite

Development of implantation substrates for the collection of radionuclides of medical interest produced via ISOL technique at INFN-LNL

Cited by 8 publications

References 44 publications

A New Production Method of High Specific Activity Radionuclides Towards Innovative Radiopharmaceuticals: The Isolpharm Project

A New Production Method of High Specific Activity Radionuclides Towards Innovative Radiopharmaceuticals: The Isolpharm Project

Lights and Shadows on the Sourcing of Silver Radioisotopes for Targeted Imaging and Therapy of Cancer: Production Routes and Separation Methods

Production and characterization of 111Ag radioisotope for medical use in a TRIGA Mark II nuclear research reactor

Contact Info

Product

Resources

About